AUS
NZ
UK
CA
USA
IND
Highlights
- New trial with Swinburne University targets binge eating disorder
- TRP-8803 infusion aims to assess impact on eating behavior, mental health
- Builds on strong Phase 2 results from prior psilocybin studies
Tryptamine Therapeutics (ASX:TRP) has taken a major step forward in the development of psychedelic-assisted therapies, launching the world’s first clinical trial using its proprietary psilocybin compound TRP-8803 to address binge eating disorder (BED). This innovative study is being conducted in collaboration with Swinburne University, led by Professor Susan Rossell.
The new 12-patient trial will explore the safety and impact of TRP-8803, an infused psilocybin formulation, on several key indicators of BED, including binge eating frequency, sense of control, food and alcohol intake, body mass index, waist circumference, anxiety, and depression. The outcomes will be evaluated four weeks after the second administered dose.
The launch of this study follows promising results from two prior investigations by Tryptamine Therapeutics. One study, conducted with the University of Florida, used an oral psilocybin formulation (IO2) and involved 26 BED patients. Participants experienced a striking 80% reduction in binge eating episodes and reported a similar decrease in the sense of loss of control. These effects were observed across both daily and weekly binge eaters and were sustained for over 60 days. Additional benefits included a 45% reduction in depression symptoms and a 60% drop in anxiety levels over a 14-week period.
A second study evaluated the safety and efficacy of TRP-8803. All participants reached a psychedelic state in under 15 minutes, with the effects lasting around two hours. The compound was well tolerated, requiring no dose adjustments—even in obese participants.
BED remains the most common eating disorder in the United States and the second most prevalent in Australia. It is frequently accompanied by serious mental health comorbidities, including depression, anxiety, PTSD, alcohol use disorder, and sleep disturbances. Tryptamine Therapeutics believes its approach has the potential to fill significant treatment gaps, particularly given the limited effectiveness of existing therapies beyond cognitive behavioral interventions.
In addition to the Swinburne trial, Tryptamine Therapeutics has several other clinical programs nearing completion. These include studies targeting irritable bowel syndrome with Massachusetts General Hospital and ongoing research into fibromyalgia and BED in the United States. Study reports from these programs are expected in the second half of the year, positioning the company for a steady stream of clinical updates and continued momentum into 2025.
